Petlife Pharmaceuticals Inc (PTLFD) 0.9500 $PTLFD
Post# of 273254
Posted On: 09/22/2016 3:16:37 AM
Petlife Pharmaceuticals Inc (PTLFD) 0.9500 $PTLFD
PetLife Pharmaceuticals Continues Execution of its Vitalzul TM Business Plan with start of Proof of Concept studies; Provides Updates
GlobeNewswire - Wed Sep 14, 8:24AM CDT
Hancock, MD - PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the "Company"
, a developer of Vitalzul(TM), a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announces plans to begin its Proof of Concept study as part of its pre-INAD (Investigational New Animal Drug) program. The study will be undertaken under contract by InnoVision Therapeutics. Proof of Concept studies are an early stage of clinical drug development when a compound has shown potential in animal models and early safety testing. These small-scale studies are designed to detect a signal that the drug is active on a pathophysiologically relevant mechanism, as well as preliminary evidence of efficacy in a clinically relevant endpoint.
PetLife Pharmaceuticals Continues Execution of its Vitalzul TM Business Plan with start of Proof of Concept studies; Provides Updates
GlobeNewswire - Wed Sep 14, 8:24AM CDT
Hancock, MD - PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the "Company"
, a developer of Vitalzul(TM), a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announces plans to begin its Proof of Concept study as part of its pre-INAD (Investigational New Animal Drug) program. The study will be undertaken under contract by InnoVision Therapeutics. Proof of Concept studies are an early stage of clinical drug development when a compound has shown potential in animal models and early safety testing. These small-scale studies are designed to detect a signal that the drug is active on a pathophysiologically relevant mechanism, as well as preliminary evidence of efficacy in a clinically relevant endpoint. 
(0)
(0)Scroll down for more posts ▼